A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
NR is well-tolerated in older adults with MCI and may enhance perfusion of the hippocampus regardless of underlying AD pathology. However, this was not associated with improved memory performance in this short-duration trial. A larger phase-III trial over a longer treatment duration is warranted to determine the efficacy of NR for delaying cognitive impairment due to ADRD.
Authors
- Catherine Awad
- Alyssa M. Lanzi (ORCID: https://orcid.org/0000-0002-6460-9283)
- Matthew L. Cohen (ORCID: https://orcid.org/0000-0001-9609-2461)
- James M. Ellison (ORCID: https://orcid.org/0000-0003-3742-1207)
- Theodore M. DeConne (ORCID: https://orcid.org/0000-0002-9704-6499)
- Fiona M. Horvat (ORCID: https://orcid.org/0000-0003-3063-420X)
- Nichole Reisdorph (ORCID: https://orcid.org/0000-0002-0425-8012)
- Faria Sanjana (ORCID: https://orcid.org/0000-0001-6529-6680)
- Kevin Decker (ORCID: https://orcid.org/0000-0001-6595-0072)
- Nicholas Rizzi
- Elizabeth Habash
- Joshua C. Hobson
- Michael Armstrong
- Curtis L Johnson
- Christopher R Martens
- Ryan T Pohlig
Institutions
- Thomas Jefferson University (US)
- Wake Forest University (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Delaware (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108851
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00